Kong Fanming, Gao Fangfang, Liu Honggen, Chen Liwei, Zheng Rongxiu, Yu Jianchun, Li Xiaojiang, Liu Geli, Jia Yingjie
Department of Oncology, First Teaching Hospital of Tianjin University of TCM, Anshanxi Road, Nankai District, Tianjin, 300193, China.
Department of Pediatrics, Tianjin Medical University General Hospital, Anshan Road, Tianjin, 300052, China.
Tumour Biol. 2015 Sep;36(10):8101-6. doi: 10.1007/s13277-015-3549-1. Epub 2015 May 16.
Metformin has been reported having potential anticancer effect on kinds of solid tumors, but its role in combined small-cell lung cancer (C-SCLC) remains indistinct. This study aimed to explore whether metformin use has a prognosis benefit in diabetic C-SCLC patients. A total of 259 C-SCLC patients with diabetes were enrolled in our study. The clinicopathological parameters and survival data were collected and analyzed. The correlation between metformin use and clinicopathological characters was analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of metformin use for C-SCLC. The metformin was used in 120 (46.3 %) patients. Our data showed that the metformin use decreased C-SCLC recurrence rate (p = 0.001). The median overall survival (OS) and disease-free survival (DFS) were significantly better in the metformin use group compared to non-metformin group (OS 19.0 vs 11.5 months, p < 0.001; DFS 10.5 vs 7.0 months, p < 0.001). Multivariate analyses indicated that metformin use was an independent prognostic factor for OS and DFS (p = 0.001 vs p = 0.018). The metformin use improved the long-term outcome of C-SCLC patients with diabetes, which might be considered a potential useful prognostic indicator and anticancer drug.
据报道，二甲双胍对多种实体瘤具有潜在的抗癌作用，但其在小细胞肺癌合并症（C-SCLC）中的作用仍不明确。本研究旨在探讨二甲双胍的使用是否对糖尿病合并小细胞肺癌（C-SCLC）患者的预后有益。共有259例糖尿病合并小细胞肺癌（C-SCLC）患者纳入本研究。收集并分析临床病理参数和生存数据。分析二甲双胍使用与临床病理特征之间的相关性。进行单因素和多因素分析，以研究二甲双胍使用对小细胞肺癌（C-SCLC）的预后意义。120例（46.3%）患者使用了二甲双胍。我们的数据显示，使用二甲双胍可降低小细胞肺癌（C-SCLC）的复发率（p = 0.001）。与未使用二甲双胍的组相比，使用二甲双胍组的中位总生存期（OS）和无病生存期（DFS）显著更好（OS为19.0个月对11.5个月，p < 0.001；DFS为10.5个月对7.0个月，p < 0.001）。多因素分析表明，使用二甲双胍是总生存期（OS）和无病生存期（DFS）的独立预后因素（p = 0.001对p = 0.018）。使用二甲双胍改善了糖尿病合并小细胞肺癌（C-SCLC）患者的长期预后，这可能被认为是一种潜在有用的预后指标和抗癌药物。
